Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + mitomycin c
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fluorouracil + mitomycin c is a combination chemotherapy regimen consisting of two cytotoxic agents—fluorouracil (also known as 5-fluorouracil or 5FU) and mitomycin c. This combination is most commonly used in conjunction with radiotherapy (chemoradiation) for the treatment of nonmetastatic anal canal cancer and muscle-invasive bladder cancer. Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, thereby interfering with DNA synthesis and function. Mitomycin c acts as an alkylating agent that crosslinks DNA, leading to inhibition of DNA synthesis and function. The synergistic effect of these drugs enhances the cytotoxic impact on rapidly dividing tumor cells when combined with radiation therapy[1][2][4][5]. The FUMIR regimen refers specifically to this drug pair given concurrently with radiation.
- Brand names
- ADRUCILEFUDEX
- Other names
- 5-fluorouracil + mitomycin c5FU + MMCFUMIR regimenmitomycin and fluorouracil
02
Targets
TXNRD2 (Thioredoxin reductase 2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + mitomycin c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + mitomycin c.